Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma
Drug Resistance Updates · 2024
DOI: 10.1016/j.drup.2024.101052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024. Verfasst von Shi-Hui Hao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-se…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Liver Neoplasms, Dual-Specificity Phosphatases. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Sun Yat-Sen University Cancer Prevention and Treatment Center.
Abstract (Originalsprache)
AIMS: This investigation aims to elucidate the mechanism underlying sorafenib-induced ferroptosis in hepatocellular carcinoma (HCC). METHODS: The role of dual specificity phosphatase 4 (DUSP4) in sorafenib-treated HCC was investigated using comprehensive assessments both in vitro and in vivo, including Western blotting, qRT-PCR, cell viability assay, lipid reactive oxygen species (ROS) assay, immunohistochemistry, and xenograft tumor mouse model. Additionally, label-free quantitative proteomics was employed to identify potential proteins associated with DUSP4. RESULTS: Our study revealed that suppression of DUSP4 expression heightens the susceptibility of HCC cells to ferroptosis inducers, specifically sorafenib and erastin, in both in vitro and in vivo settings. Furthermore, we identified DUSP4-mediated regulation of key ferroptosis-related markers, such as ferritin light chain (FTL) and ferritin heavy chain 1 (FTH1). Notably, label-free quantitative proteomics unveiled the phosphorylation of threonine residue T148 on YTH Domain Containing 1 (YTHDC1) by DUSP4. Further investigations unraveled that YTHDC1, functioning as an mRNA nuclear export regulator, is a direct target of DUSP4, orchestrating the subcellular localization of FTL and FTH1 mRNAs. Significantly, our study highlights a strong correlation between elevated DUSP4 expression and sorafenib resistance in HCC. CONCLUSIONS: Our findings introduce DUSP4 as a negative regulator of sorafenib-induced ferroptosis. This discovery opens new avenues for the development of ferroptosis-based therapeutic strategies tailored for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060 Guangzhou, China.
- Department of Liver Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Department of Anesthesiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
- Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, 510060 Guangzhou, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060 Guangzhou, China; Department of Pathology, State Key Laboratory of…
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Sun Yat-Sen University Cancer Prevention and Treatment Center
Zitieren
APA
Hao, S. H., Ma, X. D., Xu, L., Xie, J. D., Feng, Z. H., Chen, J. W., Chen, R. X., Wang, F. W., Tang, Y. H., Xie, D., & Cai, M. Y. (2024). Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2024.101052
Vancouver
Hao SH, Ma XD, Xu L, Xie JD, Feng ZH, Chen JW, et al. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug Resistance Updates. 2024. doi:10.1016/j.drup.2024.101052
BibTeX
@article{Hao2024,
author = {Hao, Shi-Hui and Ma, Xiao-Dan and Xu, Li and Xie, Jing-Dun and Feng, Zi-Hao and Chen, Jie-Wei and Chen, Ri-Xin and Wang, Feng-Wei and Tang, Yu-Hao and Xie, Dan and Cai, Mu-Yan},
title = {Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma},
journal = {Drug Resistance Updates},
year = {2024},
doi = {10.1016/j.drup.2024.101052}
}
EUVIMED